Table 3.
Nucleoside | Healthy adults | Patients with | Patients with |
intestinal villous | colorectal cancer | ||
adenoma | |||
Pseu | 22.08 ± 5.11 | 23.99 ± 5.61 | 42.19 ± 22.25a |
C | 0.15 ± 0.12 | 0.40 ± 0.21c | 0.43 ± 0.49a |
U | 0.30 ± 0.15 | 0.31 ± 0.12 | 0.31 ± 0.23 |
m1A | 2.04 ± 0.53 | 2.30 ± 0.62 | 2.74 ± 0.80a |
I | 0.28 ± 0.11 | 0.27 ± 0.11 | 0.50 ± 0.35a |
m5U | 0.04 ± 0.06 | 0.12 ± 0.06c | 0.13 ± 0.08a |
G | 0.09 ± 0.03 | 0.08 ± 0.02 | 0.10 ± 0.04 |
m1I | 1.25 ± 0.28 | 1.97 ± 0.50c | 2.76 ± 1.94a |
m1G | 0.82 ± 0.24 | 1.21 ± 0.26c | 1.44 ± 0.51a |
ac4C | 0.69 ± 0.20 | 0.70 ± 0.19 | 0.84 ± 0.30a |
m2G | 0.55 ± 0.14 | 0.52 ± 0.28 | 0.63 ± 0.26a |
A | 0.52 ± 0.16 | 0.59 ± 0.25 | 0.66 ± 0.30a |
m22G | 1.25 ± 0.23 | 1.43 ± 0.27 | 1.81 ± 0.55a |
m6A | 0.04 ± 0.02 | 0.06 ± 0.05 | 0.07 ± 0.05a |
P < 0.05 patients with colorectal cancer vs healthy adults.
P < 0.05 patients with intestinal villous adenoma vs healthy adults.